Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19399243 | 0.93 | KIF11 (0.34) | GABRA1GABRB2KIF11GABRG2GABRB3 | |
| SCHEMBL19399244 | 0.92 | L3MBTL1 (0.36) | GABRA1GABRB2KIF11PTPN2PTPN1 | |
| SCHEMBL19399255 | 0.92 | PTPN2 (0.35) | GABRA1GABRB2KIF11PTPN2PTPN1 | |
| SCHEMBL17600548 | 0.92 | KIF11 (0.36) | GABRA1GABRB2KIF11PTPN2PTPN1 | |
| SCHEMBL19399251 | 0.90 | GABRA1 (0.33) | GABRA1GABRB2KIF11PTPN2PTPN1 | |
| SCHEMBL17625265 | 0.90 | GABRA1 (0.36) | GABRA1GABRB2KIF11GABRG2GABRB3 | |
| SCHEMBL19399253 | 0.89 | L3MBTL1 (0.35) | GABRA1GABRB2KIF11PTPN2PTPN1 | |
| SCHEMBL17625231 | 0.87 | KCNH2 (0.38) | KCNH2TDP1L3MBTL1 | |
| SCHEMBL17600538 | 0.84 | KIF11 (0.39) | GABRA1GABRB2KIF11KCNH2GABRG2 | |
| SCHEMBL17600542 | 0.83 | L3MBTL1 (0.38) | GABRA1GABRB2KIF11PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186747-A1 | DIAZIRINE COMPOUNDS AND COMPOSITIONS DERIVED THEREFROM | PROMERUS, LLC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20170279048-A1 | DIAZIRINE CONTAINING ORGANIC ELECTRONIC COMPOSITIONS AND DEVICE THEREOF | PROMERUS, LLC (US) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186747-A1 | DIAZIRINE COMPOUNDS AND COMPOSITIONS DERIVED THEREFROM | ZYX, AOX1, RDX | GABRA1 1150/4885GABRB2 1211/4885KIF11 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.